Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease
2021
Hemodynamic alterations, metabolic dysfunction, inflammation, and fibrosis are the main drivers of diabetic kidney disease (DKD) progression. Targeting inflammation and fibrosis as a driver, the FIDELIO-DKD (Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes) trial reported by Bakris et al. provides evidence of a new therapeutic class for treating DKD.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
10
References
0
Citations
NaN
KQI